APA

Bedard P. L., Tabernero J., Janku F., Wainberg Z. A., Paz-Ares L., Vansteenkiste J., Van Cutsem E., Pérez-García J., Stathis A., Britten C. D., Le N., Carter K., Demanse D., Csonka D., Peters M., Zubel A., Nauwelaerts H. & Sessa C. (20151209). A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. : Clinical cancer research : an official journal of the American Association for Cancer Research.

Chicago

Bedard Philippe L, Tabernero Josep, Janku Filip, Wainberg Zev A, Paz-Ares Luis, Vansteenkiste Johan, Van Cutsem Eric, Pérez-García José, Stathis Anastasios, Britten Carolyn D, Le Ngocdiep, Carter Kirsten, Demanse David, Csonka Denes, Peters Malte, Zubel Angela, Nauwelaerts Heidi and Sessa Cristiana. 20151209. A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. : Clinical cancer research : an official journal of the American Association for Cancer Research.

Harvard

Bedard P. L., Tabernero J., Janku F., Wainberg Z. A., Paz-Ares L., Vansteenkiste J., Van Cutsem E., Pérez-García J., Stathis A., Britten C. D., Le N., Carter K., Demanse D., Csonka D., Peters M., Zubel A., Nauwelaerts H. and Sessa C. (20151209). A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. : Clinical cancer research : an official journal of the American Association for Cancer Research.

MLA

Bedard Philippe L, Tabernero Josep, Janku Filip, Wainberg Zev A, Paz-Ares Luis, Vansteenkiste Johan, Van Cutsem Eric, Pérez-García José, Stathis Anastasios, Britten Carolyn D, Le Ngocdiep, Carter Kirsten, Demanse David, Csonka Denes, Peters Malte, Zubel Angela, Nauwelaerts Heidi and Sessa Cristiana. A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. : Clinical cancer research : an official journal of the American Association for Cancer Research. 20151209.